[Market Focus] Samsung Biologics and Episholdings Weaken Together on First Day After Spin-off and Relisting

After the spin-off and relisting, both Samsung Biologics and the newly established Samsung Episholdings are experiencing declines.

As of 9:54 a.m. on the 24th, Samsung Biologics is trading at 1,669,000 won, down 128,000 won (7.12%) from the previous session. Samsung Episholdings is at 498,500 won, down 112,500 won (18.41%) from its opening price of 611,000 won.

Previously, Samsung Biologics underwent a spin-off into a surviving company (Samsung Biologics), which continues its contract development and manufacturing organization (CDMO) business, and a new company (Samsung Episholdings) responsible for investments and subsidiary management. Samsung Bioepis is in charge of the biosimilar business and new drug development.

This content was produced with the assistance of AI translation services.